The prognostic value of lymph node to primary tumor standardized uptake value ratio in cancer patients: a meta-analysis

IF 2.5 4区医学 Q2 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Annals of Nuclear Medicine Pub Date : 2024-05-09 DOI:10.1007/s12149-024-01933-5

Wing-Keen Yap, Ken-Hao Hsu, Ting-Hao Wang, Chia-Hsin Lin, Chung-Jan Kang, Shih-Ming Huang, Huan-Chun Lin, Tsung-Min Hung, Kai-Ping Chang, Tsung-You Tsai

{"title":"The prognostic value of lymph node to primary tumor standardized uptake value ratio in cancer patients: a meta-analysis","authors":"Wing-Keen Yap, Ken-Hao Hsu, Ting-Hao Wang, Chia-Hsin Lin, Chung-Jan Kang, Shih-Ming Huang, Huan-Chun Lin, Tsung-Min Hung, Kai-Ping Chang, Tsung-You Tsai","doi":"10.1007/s12149-024-01933-5","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><p>The lymph node to primary tumor standardized uptake value ratio (NTR) is an innovative parameter derived from positron emission tomography/computed tomography (PET/CT) scans that captures the intricate relationship between primary tumors and associated lymph nodes. This meta-analysis aimed to investigate the prognostic value of NTR in cancer patients.</p><h3>Methods</h3><p>A systematic search of PubMed, Cochrane, and Embase databases was conducted to identify studies investigating the association between NTR and survival outcomes in cancer patients. The pooled adjusted hazard ratios (aHRs) and 95% confidence intervals (CIs) were calculated using a random-effects model.</p><h3>Results</h3><p>Twelve studies comprising a total of 2037 patients were included in the meta-analysis. Elevated NTR was significantly associated with worse overall survival aHR (2.21, 95% CI 1.63 to 2.99), disease-free survival aHR (3.27, 95% CI 2.12 to 5.05), and distant metastasis-free survival aHR (2.07, 95% CI 1.55 to 2.78) in cancer patients. Subgroup analyses by cancer type showed consistent results across various malignancies, including head and neck squamous cell carcinoma, endometrial carcinoma, lung cancer, breast cancer, and nasopharyngeal carcinoma.</p><h3>Conclusions</h3><p>This meta-analysis provides evidence for a significant association between elevated NTR and worse survival outcomes in cancer patients. Elevated NTR may serve as a useful prognostic biomarker for cancer patients and could potentially be used to guide treatment decisions and monitor disease progression. Future studies should aim to validate these findings in larger and more diverse patient populations and investigate the underlying mechanisms for the observed association between NTR and survival outcomes.</p></div>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":"38 8","pages":"607 - 618"},"PeriodicalIF":2.5000,"publicationDate":"2024-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Nuclear Medicine","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1007/s12149-024-01933-5","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}

引用次数: 0

Abstract

Objective

The lymph node to primary tumor standardized uptake value ratio (NTR) is an innovative parameter derived from positron emission tomography/computed tomography (PET/CT) scans that captures the intricate relationship between primary tumors and associated lymph nodes. This meta-analysis aimed to investigate the prognostic value of NTR in cancer patients.

Methods

A systematic search of PubMed, Cochrane, and Embase databases was conducted to identify studies investigating the association between NTR and survival outcomes in cancer patients. The pooled adjusted hazard ratios (aHRs) and 95% confidence intervals (CIs) were calculated using a random-effects model.

Results

Twelve studies comprising a total of 2037 patients were included in the meta-analysis. Elevated NTR was significantly associated with worse overall survival aHR (2.21, 95% CI 1.63 to 2.99), disease-free survival aHR (3.27, 95% CI 2.12 to 5.05), and distant metastasis-free survival aHR (2.07, 95% CI 1.55 to 2.78) in cancer patients. Subgroup analyses by cancer type showed consistent results across various malignancies, including head and neck squamous cell carcinoma, endometrial carcinoma, lung cancer, breast cancer, and nasopharyngeal carcinoma.

Conclusions

This meta-analysis provides evidence for a significant association between elevated NTR and worse survival outcomes in cancer patients. Elevated NTR may serve as a useful prognostic biomarker for cancer patients and could potentially be used to guide treatment decisions and monitor disease progression. Future studies should aim to validate these findings in larger and more diverse patient populations and investigate the underlying mechanisms for the observed association between NTR and survival outcomes.

Abstract Image

查看原文本刊更多论文

癌症患者淋巴结与原发肿瘤标准化摄取值比值的预后价值：一项荟萃分析。

目的：淋巴结与原发肿瘤标准化摄取值比值（NTR）是从正电子发射断层扫描/计算机断层扫描（PET/CT）扫描中得出的一个创新参数，它捕捉了原发肿瘤与相关淋巴结之间错综复杂的关系。这项荟萃分析旨在研究 NTR 在癌症患者中的预后价值：方法：我们对PubMed、Cochrane和Embase数据库进行了系统检索，以确定调查NTR与癌症患者生存结果之间关系的研究。采用随机效应模型计算了汇总调整后的危险比（aHRs）和95%置信区间（CIs）：荟萃分析共纳入了 12 项研究，共计 2037 名患者。NTR升高与癌症患者较差的总生存率aHR（2.21，95% CI 1.63-2.99）、无病生存率aHR（3.27，95% CI 2.12-5.05）和无远处转移生存率aHR（2.07，95% CI 1.55-2.78）明显相关。按癌症类型进行的分组分析显示，头颈部鳞状细胞癌、子宫内膜癌、肺癌、乳腺癌和鼻咽癌等各种恶性肿瘤的结果一致：这项荟萃分析提供了证据，证明 NTR 升高与癌症患者生存状况恶化之间存在显著关联。NTR升高可作为癌症患者的一种有用的预后生物标志物，并有可能用于指导治疗决策和监测疾病进展。未来的研究应着眼于在更大规模和更多样化的患者群体中验证这些发现，并调查所观察到的 NTR 与生存结果之间关联的潜在机制。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Annals of Nuclear Medicine 医学-核医学

CiteScore

4.90

自引率

7.70%

发文量

111

审稿时长

4-8 weeks

期刊介绍： Annals of Nuclear Medicine is an official journal of the Japanese Society of Nuclear Medicine. It develops the appropriate application of radioactive substances and stable nuclides in the field of medicine. The journal promotes the exchange of ideas and information and research in nuclear medicine and includes the medical application of radionuclides and related subjects. It presents original articles, short communications, reviews and letters to the editor.